Abstract: A magnetic resonance imaging scanner acquires diffusion-weighted imaging data. A reconstruction engine reconstructs the acquired diffusion-weighted imaging data into diffusion-weighted image representations. A diffusion tensor engine constructs a diffusion tensor map of an area of an interest of a subject. An eigenvalue/eigenvector ordering engine obtains and orders eigenvectors and eigenvalues at each voxel. A covariance matrix determining engine constructs a covariance matrix of a major eigenvector of each voxel. A first normalized measure determining engine computes a first normalized measure. A second normalized measure determining engine computes a second normalized measure. A rendering engine generates a human-viewable display of an image representation.
Type:
Grant
Filed:
November 3, 2008
Date of Patent:
March 15, 2011
Assignee:
The United States of America as represented by the Department of Health and Human Services
Abstract: The present invention relates to the use of genes differentially expressed in benign thyroid lesions and malignant thyroid lesions for the diagnosis and staging of thyroid cancer.
Type:
Grant
Filed:
April 11, 2005
Date of Patent:
March 8, 2011
Assignees:
The United States of America as represented by the Department of Health and Human Services, The John Hopkins University
Inventors:
Steven K. Libutti, Chiara Mazzanti, Martha Zeiger, Christopher Umbricht
Abstract: An isolated polynucleotide encodes JAK-3 protein. JAK-3 protein is a protein tyrosine kinase having a molecular weight of approximately 125 kDa which has tandem non-identical catalytic domains, lacks SH2 or SH3 domains, and is expressed in NK cells and stimulated or transformed T cells, but not in resting T cells. The protein itself and antibodies to this protein are also presented. Further, methods of identifying therapeutic agents for modulating the immune system make use of the foregoing.
Type:
Grant
Filed:
January 15, 2009
Date of Patent:
March 8, 2011
Assignee:
The United States of America as represented by the Department of Health and Human Services
Inventors:
John J. O'Shea, Warren J. Leonard, James A. Johnston, Sarah M. Russell, Daniel W. McVicar, Masaru Kawamura
Abstract: Tumor suppressor genes play a major role in the pathogenesis of human lung cancer and other cancers. Cytogenetic and allelotyping studies of fresh tumor and tumor-derived cell lines showed that cytogenetic changes and allele loss on the short arm of chromosome 3 (3p) are most frequently involved in about 90% of small cell lung cancers and greater than 50% of non-small cell lung cancers. A group of recessive oncogenes, Fus1, 101F6, Gene 21 (NPRL2), Gene 26 (CACNA2D2), Luca 1 (HYAL1), Luca 2 (HYAL2), PL6, 123F2 (RaSSFI), SEM A3 and Beta* (BLU), as defined by homozygous deletions in lung cancers, have been located and isolated at 3p21.3.
Type:
Grant
Filed:
May 27, 2003
Date of Patent:
March 8, 2011
Assignees:
Board of Regents, The University of Texas, The United States of America as represented by the Department of Health and Human Services
Inventors:
Lin Ji, John Dorrance Minna, Jack Roth, Michael Lerman
Abstract: A new polypeptide is disclosed that is specifically detected in the cells of the prostate, termed Novel Gene Expressed in Prostate (NGEP). Polynucleotides encoding NGEP are also disclosed, as are vectors including these polynucleotides. Host cells transformed with these polynucleotides are also disclosed. Antibodies are disclosed that specifically bind NGEP. Methods are disclosed for using an NGEP polypeptide, an antibody that specifically binds NGEP, or a polynucleotide encoding NGEP. Assays are disclosed for the detection prostate cancer. Pharmaceutical compositions including an NGEP polypeptide, an antibody that specifically binds NGEP, or a polynucleotide encoding NGEP are also disclosed. These pharmaceutical compositions are of use in the treatment of prostate cancer.
Type:
Grant
Filed:
August 18, 2008
Date of Patent:
March 1, 2011
Assignee:
The United States of America as represented by the Department of Health and Human Services
Inventors:
Ira H. Pastan, Tapan K. Bera, Curt Wolfgang, Byungkook Lee, James Vincent
Abstract: The invention relates to compositions and methods for treating or preventing vascular dementia in a mammal comprising mucosal administration of an amount of E-selectin polypeptide sufficient to induce bystander immune tolerance in the mammal. Another aspect of the invention relates to compositions useful for treating or preventing vascular dementia.
Type:
Grant
Filed:
February 28, 2008
Date of Patent:
March 1, 2011
Assignee:
The United States of America as represented by the Department of Health and Human Services
Abstract: It is disclosed herein that agents that affect the activity and/or expression of CXCL16 can be used to alter the uptake of D-type CpG oligodeoxynucleotides (D ODNs). Methods of inducing an immune response are disclosed that include administering agents that increase the activity and/or expression of CXCL16 and a D ODN. Methods of decreasing an immune response to a CpG ODN are also disclosed. These methods include administering an agent that decreases the activity and/or expression of CXCL16. Compositions including one or more D-type ODNs and an agent that modulates that activity and/or expression of CXCL16 are provided.
Type:
Grant
Filed:
August 28, 2006
Date of Patent:
February 22, 2011
Assignee:
The United States of America as represented by the Department of Health and Human Services
Inventors:
Dennis M. Klinman, Mayda Gursel, Ihsan Gursel
Abstract: The present invention provides methods an compositions for diagnosis and treatment of carcinomas with aberrant expression patterns of POT 1. The invention also provides methods of identifying compounds that may modulate the cellular expression of POT 1. The invention further provides methods for treating subjects suffering from or at risk of developing a colorectal carcinoma.
Type:
Grant
Filed:
October 19, 2005
Date of Patent:
February 22, 2011
Assignee:
The United States of America as represented by the Department of Health and Human Services
Abstract: A countercurrent chromatography apparatus includes a plurality of plates, at least one plate (16) having first and second interleaved spiral flow channels (52, 54, 56, 58) therein. Each spiral flow channels (52, 54, 56, 58) has a first end (I1, I2, I3, I4) near the central axis and a second ends (O1, O2, O3, O4) near the periphery. The outlet of the first channel (O1) is connected to the inlet of the second channel (I2) by a connecting channel (72). Septa may be provided between the plates to connect the spiral channels of one plate to the spiral channels of the next plate.
Type:
Grant
Filed:
March 25, 2003
Date of Patent:
February 22, 2011
Assignee:
The United States of America as represented by the Department of Health and Human Services
Abstract: The present invention relates to a method of expressing an immunotoxin in Pichia pastoris strain mutated to toxin resistance comprising a) growing the Pichia pastoris in a growth medium comprising an enzymatic digest of protein and yeast extract and maintaining a dissolved oxygen concentration at 40% and above; and b) performing methanol induction with a limited methanol feed of 0.5-0.75 ml/min/IO L of initial volume during induction along with a continuous infusion of yeast extract at a temperature below 17.5° C., antifoaming agent supplied up to 0.07%, agitation reduced to 400 RPM, and the induction phase extended out to 163 h.
Type:
Grant
Filed:
August 2, 2004
Date of Patent:
February 22, 2011
Assignee:
The United States of America as represented by the Department of Health and Human Services
Inventors:
David M. Neville, Jung-Hee Woo, Yuan-Yi Liu
Abstract: Optical cells include a spacer formed of a hydrocarbon-resistant polymer, so that fluids such as hydrocarbons and alcohols can be introduced to a sample space, or include a fluid inlet and a heated inlet tube, so that a humid gas can be introduced to the sample space without condensation occurring. Optical cells can be used with, for example, solid, gel, and liquid samples. Measurements can be performed with various selected sample gaps of an optical cell.
Type:
Grant
Filed:
July 18, 2007
Date of Patent:
February 22, 2011
Assignee:
The United States of America as represented by the Department of Health and Human Services
Abstract: Compositions, methods and devices for the detection of anti-lipoidal antibodies and the diagnosis of disease, for example, syphilis, are described. In particular, oxidized cardiolipins, which may be conjugated with a variety of attachment molecules, such as BSA, KLH, biotin, synthetic protein MAPS, IgY, streptavidin, or avidin, are described. Such oxidized cardiolipin, alone or complexed with one or more attachment molecules, are useful to detect anti-lipoidal antibodies in subjects, for example, when used in lateral flow devices. Lateral flow devices are described that permit the detection of anti-lipoidal antibodies and that permit the co-detection of nontreponemal and treponemal antibodies in biological samples.
Type:
Grant
Filed:
November 17, 2006
Date of Patent:
February 15, 2011
Assignee:
The United States of America as represented by the Department of Health and Human Services, Centers for Disease Control and Prevention
Abstract: This invention relates to compositions and methods for the detection of HIV-1 antibodies employing polypeptides obtained from the Gag-p6 protein, the method comprising the steps of: (a) contacting a biological sample with a peptide having an epitope that is recognized by the anti-HIV-1 antibody where the contacting is under conditions sufficient to permit anti-HIV-1 present in the sample to bind to the epitope and form a peptide-anti-HIV-1 antibody complex; (b) contacting the formed peptide-anti-HIV-1 antibody complex with an anti-HIV-1 antibody binding molecule under conditions sufficient to permit the anti-HIV-1 antibody binding molecule to bind to anti-HIV-1 antibody of the formed peptide-anti-HIV-1 antibody complex and form an extended complex; said extended complex being immobilized on a solid support; and (c) removing unbound antibody from said extended complex; and (d) determining the presence or concentration of the anti-HIV-1 antibody in the biological sample by determining the presence or concentrat
Type:
Grant
Filed:
September 2, 2005
Date of Patent:
February 15, 2011
Assignee:
The United States of America as represented by the Department of Health and Human Services
Abstract: Targeted disruption of the centrin gene leads to attenuation of growth in Leishmania. Preferred embodiments of the invention provide attenuated strains of Leishmania useful for the preparation of immunogenic preparations including vaccines against a disease caused by infection with a virulent Leishmania strain and as tools for the generation of immunological and diagnostic reagents. Other preferred embodiments provide related immunogenic compositions, methods of generating an immune response, methods for producing a vaccine, and methods of forming attenuated strains of Leishmania.
Type:
Grant
Filed:
February 28, 2006
Date of Patent:
February 15, 2011
Assignee:
The United States of America as represented by the Department of Health and Human Services
Inventors:
Hira L. Nakhasi, Angamuthu Selvapandiyan, Alain Debrabant, Robert C. Duncan, Poonam Salotra, Gannavaram Sreenivas
Abstract: Disclosed are methods for identifying and isolating a precursor cell. Also, disclosed are methods of increasing insulin synthesis from a pancreatic B-cell. Further, disclosed are methods of improving pancreatic B-cell function. Still further, disclosed are methods of preventing or delaying the onset of a metabolic disease, methods of treating or preventing a metabolic disease in a subject, and to compositions for treating or preventing a metabolic disease in a subject in need of such treatment or prevention.
Type:
Grant
Filed:
July 22, 2005
Date of Patent:
February 15, 2011
Assignee:
The United States of America as represented by the Department of Health and Human Services
Abstract: An isolated and purified nucleic acid molecule that encodes a polypeptide comprising at least eight contiguous amino acids of SEQ ID NO: 3, wherein the at least eight contiguous amino acids have anti-viral activity, as well as an isolated and purified nucleic acid molecule that encodes a polypeptide comprising at least eight contiguous amino acids of SEQ ID NO: 3, wherein the at least eight contiguous amino acids have anti-viral activity, and, when the at least eight contiguous amino acids comprise amino acids 1-121 of SEQ ID NO: 3, the at least eight contiguous amino acids have been rendered glycosylation-resistant, a vector comprising such an isolated and purified nucleic acid molecule, a host cell comprising the nucleic acid molecule, optionally in the form of a vector, a method of producing an anti-viral polypeptide or conjugate thereof, the anti-viral polypeptide itself, a conjugate or fusion protein comprising the anti-viral polypeptide, and compositions comprising an effective amount of the anti-viral
Type:
Grant
Filed:
May 27, 2005
Date of Patent:
February 8, 2011
Assignee:
The United States of America as represented by the Department of Health and Human Services
Inventors:
Michael R. Boyd, Toshiyuki Mori, Barry R. O'Keefe
Abstract: This invention, in one aspect, relates to synthetic immunoreactive peptides. These peptides are approximately 20-25 amino acids in length which are portions of the N termini of the M proteins of the most prevalent United States (U.S.) Group A Streptococcus (GAS) serotypes. At least some of the synthetic peptides can be recognized by M type-specific antibodies and are capable of eliciting functional opsonic antibodies and/or anti-attachment antibodies without eliciting tissue cross-reactive antibodies. In another aspect, it relates to compositions or vaccines comprising these synthetic serotype-specific peptides, including polypeptides and proteins. The invention may also be isolated antibodies which are raised in response to the peptides, compositions or vaccines. The invention further relates to kits for using the peptides, compositions, or antibodies.
Type:
Grant
Filed:
June 23, 2008
Date of Patent:
February 8, 2011
Assignee:
The United States of America as represented by the Department of Health and Human Services
Inventors:
Bernard W. Beall, George M. Carlone, Jacquelyn S. Sampson, Edwin W. Ades
Abstract: Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed.
Type:
Grant
Filed:
October 1, 2004
Date of Patent:
February 1, 2011
Assignees:
University of Iowa Research Foundation, The United States of America, as represented by the Department of Health and Human Services, Coley Pharmaceutical Group, Inc.
Inventors:
Arthur M. Krieg, Dennis Klinman, Alfred D. Steinberg
Abstract: The invention is directed to materials and methods associated with polymorphic variants in two enzymes involved in folate-dependent and one-carbon metabolic pathways: MTHFD1 (5,10-methylenetetrahydrofolate dehydrogenase, 5,10-methenyltetrahydrofolate cyclohydrolase, 10-formyltetrahydrofolate synthetase) and methylenetetrahydrofolate dehydrogenase (NADP+dependent) 1-like (MTHFD1L). Diagnostic and therapeutic methods are provided involving the correlation of polymorphic variants in MTHFD1, MTHFD1, and other genes with relative susceptibility for various pregnancy-related and other complications.
Type:
Grant
Filed:
December 17, 2007
Date of Patent:
February 1, 2011
Assignees:
The United States of America as represented by the Department of Health and Human Services, The Provost Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth Near Dublin, The Health Research Board
Inventors:
Lawrence C. Brody, Anne Parle-McDermott, John Scott, Peadar Kirke, James Mills, Faith Pangilinan, Anne Molloy
Abstract: A method for fat-suppressed imaging is disclosed. Such a method may include storing a first spectral component of an echo signal formed at TR/2 from a sample, suppressing a second spectral component of the echo signal at TR/2, re-exciting the stored spectral component after suppressing the second spectral component, and producing an image of the sample based on the re-excited stored spectral component.
Type:
Grant
Filed:
May 21, 2007
Date of Patent:
February 1, 2011
Assignee:
The United States of America as represented by the Department of Health and Human Services
Inventors:
John Andrew Derbyshire, Daniel Alfredo Herzka, Elliot R. McVeigh